All trades / GH
GH
Guardant Health, Inc.
1,023Open-market trades
−0.15%Avg 90d after buys
−3.42%Avg 90d after sales
−20.5%Avg 180d after buys
Price and insider prints
GH adjusted close▲ buy▼ sale
Trades
| Date | Form 4 | Ticker | Insider | Title | Side | Shares | Value | 90d | 180d |
|---|---|---|---|---|---|---|---|---|---|
| 9/16/2026 | Form 4 | GH | Krognes Steve E.Steve Krognes has served as a member of our Board since June 2022. Mr. Krognes is a professional independent board member in the biotech and life sciences sector. Before joining the Board, Mr. Krognes was the Chief Financial Officer at Denali Therapeutics Inc., a public biotechnology company, from October 2015 to April 2022. Mr. Krognes joined Denali from Genentech, Inc., a biotechnology company, where he served as Chief Financial Officer and a member of the Executive Committee from April 2009 to September 2015. Mr. Krognes also oversaw Genentech’s Site Services organization between 2011 and 2015, and Genentech’s IT organization between 2009 and 2011. He chaired the Genentech Access to Care Foundation… | Director | SELL | 971 | $172.3K | +7.65%hist | +10.6%hist |
| 9/16/2026 | Form 4 | GH | Krognes Steve E.Steve Krognes has served as a member of our Board since June 2022. Mr. Krognes is a professional independent board member in the biotech and life sciences sector. Before joining the Board, Mr. Krognes was the Chief Financial Officer at Denali Therapeutics Inc., a public biotechnology company, from October 2015 to April 2022. Mr. Krognes joined Denali from Genentech, Inc., a biotechnology company, where he served as Chief Financial Officer and a member of the Executive Committee from April 2009 to September 2015. Mr. Krognes also oversaw Genentech’s Site Services organization between 2011 and 2015, and Genentech’s IT organization between 2009 and 2011. He chaired the Genentech Access to Care Foundation… | Director | SELL | 1,300 | $229.2K | +7.65%hist | +10.6%hist |
| 9/16/2026 | Form 4 | GH | Krognes Steve E.Steve Krognes has served as a member of our Board since June 2022. Mr. Krognes is a professional independent board member in the biotech and life sciences sector. Before joining the Board, Mr. Krognes was the Chief Financial Officer at Denali Therapeutics Inc., a public biotechnology company, from October 2015 to April 2022. Mr. Krognes joined Denali from Genentech, Inc., a biotechnology company, where he served as Chief Financial Officer and a member of the Executive Committee from April 2009 to September 2015. Mr. Krognes also oversaw Genentech’s Site Services organization between 2011 and 2015, and Genentech’s IT organization between 2009 and 2011. He chaired the Genentech Access to Care Foundation… | Director | SELL | 3,300 | $578.9K | +7.65%hist | +10.6%hist |
| 9/16/2026 | Form 4 | GH | Krognes Steve E.Steve Krognes has served as a member of our Board since June 2022. Mr. Krognes is a professional independent board member in the biotech and life sciences sector. Before joining the Board, Mr. Krognes was the Chief Financial Officer at Denali Therapeutics Inc., a public biotechnology company, from October 2015 to April 2022. Mr. Krognes joined Denali from Genentech, Inc., a biotechnology company, where he served as Chief Financial Officer and a member of the Executive Committee from April 2009 to September 2015. Mr. Krognes also oversaw Genentech’s Site Services organization between 2011 and 2015, and Genentech’s IT organization between 2009 and 2011. He chaired the Genentech Access to Care Foundation… | Director | SELL | 1,103 | $192.4K | +7.65%hist | +10.6%hist |
| 9/16/2026 | Form 4 | GH 10b5-1 | Azar Alex M II | Director | SELL | 826 | $144.6K | — | — |
| 9/16/2026 | Form 4 | GH 10b5-1 | Tariq MusaMusa Tariq has served as a member of our Board since March 2023. Mr. Tariq is the Founder of Science x Story, a brand driven growth consultancy that creates value at the intersection of business, marketing and organizational strategy. Prior to this, Mr. Tariq served as Chief Marketing Officer of GoFundMe, a crowdfunding platform, from January 2021 to June 2023. He joined GoFundMe to further build the GoFundMe brand and drive the company’s marketing and communications functions. Prior to GoFundMe, Mr. Tariq was Global Head of Marketing for Airbnb Experiences, a division of Airbnb, Inc., a provider of an online marketplace for short-term homestays and experiences, from September 2018 to December 2020 where he… | Director | SELL | 116 | $20.3K | −33.7%hist | −57.4%hist |
| 9/15/2026 | Form 4 | GH | Chudova DaryaDr. Chudova has served as our Chief Technology Officer since May 2023. She has been with Guardant Health since August 2015, most recently serving as Senior Vice President of Technology. In this role, she initially focused on leading technical development of Guardant360 Liquid and CDx products improving the precision, robustness and accessibility of Guardant’s liquid biopsy tests. Most recently, she has led the development of Guardant’s Shield TM technology for blood-based colorectal cancer screening, which has now been approved by the U.S. Food and Drug Administration. Prior to Guardant, Dr. Chudova successfully developed non-invasive prenatal testing at Illumina, Inc. from March 2013 to August 2015 and… | Chief Technology Officer | SELL | 7,738 | $1.38M | +13.3%hist | −22.1%hist |
| 9/11/2026 | Form 4 | GH | Kalia KumudMr. Kalia has served as our Chief Information Officer since January 2020. He most recently served as Chief Information and Technology Officer as well as other executive roles at Cylance, Inc., from March 2018 to June 2019, and previously served as Chief Information Officer at Akamai Technologies from October 2011 to February 2018. Prior to Akamai, Mr. Kalia worked at Direct Energy, an energy and services business operating in the U.S. and Canada, from March 2005 to January 2011, and where at the time of his departure he was the Chief Information Officer and Executive Vice President of Customer Operations. Earlier in his career, Mr. Kalia was Vice President and Chief Information Officer of the Business… | Chief Information Officer | SELL | 4,000 | $632.2K | −7.18%hist | −21.4%hist |
| 8/21/2026 | Form 4 | GH | Talasaz AmirAli | Co-Chief Executive Officer | SELL | 9,023 | $1.52M | −1.51%hist | −3.15%hist |
| 8/21/2026 | Form 4 | GH | Talasaz AmirAli | Co-Chief Executive Officer | SELL | 20,888 | $3.53M | −1.51%hist | −3.15%hist |
| 8/21/2026 | Form 4 | GH | Talasaz AmirAli | Co-Chief Executive Officer | SELL | 7,589 | $1.29M | −1.51%hist | −3.15%hist |
| 8/17/2026 | Form 4 | GH 10b5-1 | Tariq MusaMusa Tariq has served as a member of our Board since March 2023. Mr. Tariq is the Founder of Science x Story, a brand driven growth consultancy that creates value at the intersection of business, marketing and organizational strategy. Prior to this, Mr. Tariq served as Chief Marketing Officer of GoFundMe, a crowdfunding platform, from January 2021 to June 2023. He joined GoFundMe to further build the GoFundMe brand and drive the company’s marketing and communications functions. Prior to GoFundMe, Mr. Tariq was Global Head of Marketing for Airbnb Experiences, a division of Airbnb, Inc., a provider of an online marketplace for short-term homestays and experiences, from September 2018 to December 2020 where he… | Director | SELL | 116 | $18.1K | −33.7%hist | −57.4%hist |
| 8/12/2026 | Form 4 | GH | Monroe Terilyn J.Ms. Monroe has served as our Chief People Officer since January 2024. She most recently served as Chief People Officer at Bonterra, a SaaS, PE backed company focused on accelerating social impact through technology, from November 2021 to September 2023, and previously served as Chief People Officer, SVP People & Places at Varian from October 2017 to April 2021. Prior to Varian, Ms. Monroe worked as Chief People & Culture Officer, SVP Human Resources at Acxiom from 2015 to 2017. She also was Chief Diversity Officer at Intuit, where she led the company’s diversity and inclusion efforts, and held various roles in the Human Resources organization from 2002 to 2015. Ms. Monroe serves on the board of directors… | Chief People Officer | SELL | 3,704 | $605.3K | +7.81%hist | −31.0%hist |
| 8/12/2026 | Form 4 | GH | Monroe Terilyn J.Ms. Monroe has served as our Chief People Officer since January 2024. She most recently served as Chief People Officer at Bonterra, a SaaS, PE backed company focused on accelerating social impact through technology, from November 2021 to September 2023, and previously served as Chief People Officer, SVP People & Places at Varian from October 2017 to April 2021. Prior to Varian, Ms. Monroe worked as Chief People & Culture Officer, SVP Human Resources at Acxiom from 2015 to 2017. She also was Chief Diversity Officer at Intuit, where she led the company’s diversity and inclusion efforts, and held various roles in the Human Resources organization from 2002 to 2015. Ms. Monroe serves on the board of directors… | Chief People Officer | SELL | 9,934 | $1.63M | +7.81%hist | −31.0%hist |
| 8/12/2026 | Form 4 | GH | Monroe Terilyn J.Ms. Monroe has served as our Chief People Officer since January 2024. She most recently served as Chief People Officer at Bonterra, a SaaS, PE backed company focused on accelerating social impact through technology, from November 2021 to September 2023, and previously served as Chief People Officer, SVP People & Places at Varian from October 2017 to April 2021. Prior to Varian, Ms. Monroe worked as Chief People & Culture Officer, SVP Human Resources at Acxiom from 2015 to 2017. She also was Chief Diversity Officer at Intuit, where she led the company’s diversity and inclusion efforts, and held various roles in the Human Resources organization from 2002 to 2015. Ms. Monroe serves on the board of directors… | Chief People Officer | SELL | 19,014 | $3.14M | +7.81%hist | −31.0%hist |
| 8/12/2026 | Form 4 | GH | Monroe Terilyn J.Ms. Monroe has served as our Chief People Officer since January 2024. She most recently served as Chief People Officer at Bonterra, a SaaS, PE backed company focused on accelerating social impact through technology, from November 2021 to September 2023, and previously served as Chief People Officer, SVP People & Places at Varian from October 2017 to April 2021. Prior to Varian, Ms. Monroe worked as Chief People & Culture Officer, SVP Human Resources at Acxiom from 2015 to 2017. She also was Chief Diversity Officer at Intuit, where she led the company’s diversity and inclusion efforts, and held various roles in the Human Resources organization from 2002 to 2015. Ms. Monroe serves on the board of directors… | Chief People Officer | SELL | 13,248 | $2.20M | +7.81%hist | −31.0%hist |
| 8/12/2026 | Form 4 | GH | Monroe Terilyn J.Ms. Monroe has served as our Chief People Officer since January 2024. She most recently served as Chief People Officer at Bonterra, a SaaS, PE backed company focused on accelerating social impact through technology, from November 2021 to September 2023, and previously served as Chief People Officer, SVP People & Places at Varian from October 2017 to April 2021. Prior to Varian, Ms. Monroe worked as Chief People & Culture Officer, SVP Human Resources at Acxiom from 2015 to 2017. She also was Chief Diversity Officer at Intuit, where she led the company’s diversity and inclusion efforts, and held various roles in the Human Resources organization from 2002 to 2015. Ms. Monroe serves on the board of directors… | Chief People Officer | SELL | 400 | $67.2K | +7.81%hist | −31.0%hist |
| 8/10/2026 | Form 4 | GH | Freeman Chris | Chief Commercial Officer | SELL | 3,463 | $579.6K | +5.05%hist | −24.5%hist |
| 8/10/2026 | Form 4 | GH | Freeman Chris | Chief Commercial Officer | SELL | 7,365 | $1.24M | +5.05%hist | −24.5%hist |
| 8/10/2026 | Form 4 | GH | Freeman Chris | Chief Commercial Officer | SELL | 35,364 | $6.00M | +5.05%hist | −24.5%hist |
| 8/10/2026 | Form 4 | GH | Freeman Chris | Chief Commercial Officer | SELL | 17,413 | $2.96M | +5.05%hist | −24.5%hist |
| 8/5/2026 | Form 4 | GH | Hidalgo Medina Manuel | Director | SELL | 950 | $155.7K | −26.2%hist | −35.5%hist |
| 8/5/2026 | Form 4 | GH | Hidalgo Medina Manuel | Director | SELL | 750 | $123.5K | −26.2%hist | −35.5%hist |
| 8/4/2026 | Form 4 | GH | CLARK IAN TIan Clark has served as a member of our Board since January 2017 and is our lead independent director. Mr. Clark most recently served as CEO, led the Executive Committee, and was a member of the Board of Directors of Genentech Inc., a biotechnology company, from January 2010 to December 2016. In total he served for 14 years at Genentech of which 12 were on the Genentech Executive Committee, initially as Executive Vice President of Commercial Operations. Before that, he served as Senior Vice President and General Manager of BioOncology. Prior to this, Mr. Clark spent 20 years in positions of increasing responsibility at Novartis, Sanofi, Ivax, and Searle, working in the United Kingdom, Canada, Eastern Europe… | Director | SELL | 9,088 | $1.44M | −7.91%hist | −10.8%hist |
| 8/4/2026 | Form 4 | GH | CLARK IAN TIan Clark has served as a member of our Board since January 2017 and is our lead independent director. Mr. Clark most recently served as CEO, led the Executive Committee, and was a member of the Board of Directors of Genentech Inc., a biotechnology company, from January 2010 to December 2016. In total he served for 14 years at Genentech of which 12 were on the Genentech Executive Committee, initially as Executive Vice President of Commercial Operations. Before that, he served as Senior Vice President and General Manager of BioOncology. Prior to this, Mr. Clark spent 20 years in positions of increasing responsibility at Novartis, Sanofi, Ivax, and Searle, working in the United Kingdom, Canada, Eastern Europe… | Director | SELL | 5,092 | $808.6K | −7.91%hist | −10.8%hist |
| 7/16/2026 | Form 4 | GH 10b5-1 | Tariq MusaMusa Tariq has served as a member of our Board since March 2023. Mr. Tariq is the Founder of Science x Story, a brand driven growth consultancy that creates value at the intersection of business, marketing and organizational strategy. Prior to this, Mr. Tariq served as Chief Marketing Officer of GoFundMe, a crowdfunding platform, from January 2021 to June 2023. He joined GoFundMe to further build the GoFundMe brand and drive the company’s marketing and communications functions. Prior to GoFundMe, Mr. Tariq was Global Head of Marketing for Airbnb Experiences, a division of Airbnb, Inc., a provider of an online marketplace for short-term homestays and experiences, from September 2018 to December 2020 where he… | Director | SELL | 116 | $18.9K | −33.7%hist | −57.4%hist |
| 6/29/2026 | Form 4 | GH 10b5-1 | Talasaz AmirAli | Co-Chief Executive Officer | SELL | 70,513 | $10.68M | −1.51%hist | −3.15%hist |
| 6/29/2026 | Form 4 | GH 10b5-1 | Talasaz AmirAli | Co-Chief Executive Officer | SELL | 25,812 | $3.89M | −1.51%hist | −3.15%hist |
| 6/29/2026 | Form 4 | GH 10b5-1 | Talasaz AmirAli | Co-Chief Executive Officer | SELL | 40 | $6.1K | −1.51%hist | −3.15%hist |
| 6/29/2026 | Form 4 | GH 10b5-1 | Talasaz AmirAli | Co-Chief Executive Officer | SELL | 46,663 | $7.10M | −1.51%hist | −3.15%hist |
| 6/26/2026 | Form 4 | GH 10b5-1 | Talasaz AmirAli | Co-Chief Executive Officer | SELL | 64,037 | $9.64M | −1.51%hist | −3.15%hist |
| 6/26/2026 | Form 4 | GH 10b5-1 | Talasaz AmirAli | Co-Chief Executive Officer | SELL | 52,935 | $8.00M | −1.51%hist | −3.15%hist |
| 6/22/2026 | Form 4 | GH 10b5-1 | Tariq MusaMusa Tariq has served as a member of our Board since March 2023. Mr. Tariq is the Founder of Science x Story, a brand driven growth consultancy that creates value at the intersection of business, marketing and organizational strategy. Prior to this, Mr. Tariq served as Chief Marketing Officer of GoFundMe, a crowdfunding platform, from January 2021 to June 2023. He joined GoFundMe to further build the GoFundMe brand and drive the company’s marketing and communications functions. Prior to GoFundMe, Mr. Tariq was Global Head of Marketing for Airbnb Experiences, a division of Airbnb, Inc., a provider of an online marketplace for short-term homestays and experiences, from September 2018 to December 2020 where he… | Director | SELL | 1,951 | $255.9K | −33.7%hist | −57.4%hist |
| 6/22/2026 | Form 4 | GH 10b5-1 | POTTER MYRTLE SMyrtle Potter has served as a member of our Board since October 2021. Ms. Potter most recently served as President, Chief Executive Officer and Chairperson of the Board of Sumitomo Pharma America, Inc. from July 1, 2023 to April 1, 2024. Prior to this, Ms. Potter served as the Chief Executive Officer of Sumitovant Biopharma, Inc., a subsidiary of Sumitovant Biopharma Ltd., from December 2019 to July 2023, when Sumitomo Pharma America, Inc. announced its launch resulting from the combination of Sumitovant and its wholly owned U.S. subsidiaries and other U.S. Sumitomo Pharma wholly owned subsidiaries. Previously, from 2018 to 2019, Ms. Potter served as Vant Operating Chair at Roivant Sciences, Ltd., and as… | Director | SELL | 1,556 | $204.1K | −39.7%hist | −67.6%hist |
| 6/16/2026 | Form 4 | GH 10b5-1 | Tariq MusaMusa Tariq has served as a member of our Board since March 2023. Mr. Tariq is the Founder of Science x Story, a brand driven growth consultancy that creates value at the intersection of business, marketing and organizational strategy. Prior to this, Mr. Tariq served as Chief Marketing Officer of GoFundMe, a crowdfunding platform, from January 2021 to June 2023. He joined GoFundMe to further build the GoFundMe brand and drive the company’s marketing and communications functions. Prior to GoFundMe, Mr. Tariq was Global Head of Marketing for Airbnb Experiences, a division of Airbnb, Inc., a provider of an online marketplace for short-term homestays and experiences, from September 2018 to December 2020 where he… | Director | SELL | 116 | $15.1K | −31.8% | −57.4%hist |
| 6/15/2026 | Form 4 | GH | Kalia KumudMr. Kalia has served as our Chief Information Officer since January 2020. He most recently served as Chief Information and Technology Officer as well as other executive roles at Cylance, Inc., from March 2018 to June 2019, and previously served as Chief Information Officer at Akamai Technologies from October 2011 to February 2018. Prior to Akamai, Mr. Kalia worked at Direct Energy, an energy and services business operating in the U.S. and Canada, from March 2005 to January 2011, and where at the time of his departure he was the Chief Information Officer and Executive Vice President of Customer Operations. Earlier in his career, Mr. Kalia was Vice President and Chief Information Officer of the Business… | Chief Information Officer | SELL | 600 | $78.6K | −29.3% | −21.4%hist |
| 6/15/2026 | Form 4 | GH | Kalia KumudMr. Kalia has served as our Chief Information Officer since January 2020. He most recently served as Chief Information and Technology Officer as well as other executive roles at Cylance, Inc., from March 2018 to June 2019, and previously served as Chief Information Officer at Akamai Technologies from October 2011 to February 2018. Prior to Akamai, Mr. Kalia worked at Direct Energy, an energy and services business operating in the U.S. and Canada, from March 2005 to January 2011, and where at the time of his departure he was the Chief Information Officer and Executive Vice President of Customer Operations. Earlier in his career, Mr. Kalia was Vice President and Chief Information Officer of the Business… | Chief Information Officer | BUY | 600 | $78.5K | +29.3% | −21.4%hist |
| 6/11/2026 | Form 4 | GH | Kalia KumudMr. Kalia has served as our Chief Information Officer since January 2020. He most recently served as Chief Information and Technology Officer as well as other executive roles at Cylance, Inc., from March 2018 to June 2019, and previously served as Chief Information Officer at Akamai Technologies from October 2011 to February 2018. Prior to Akamai, Mr. Kalia worked at Direct Energy, an energy and services business operating in the U.S. and Canada, from March 2005 to January 2011, and where at the time of his departure he was the Chief Information Officer and Executive Vice President of Customer Operations. Earlier in his career, Mr. Kalia was Vice President and Chief Information Officer of the Business… | Chief Information Officer | SELL | 3,418 | $445.2K | −24.4% | −21.4%hist |
| 6/10/2026 | Form 4 | GH | Kalia KumudMr. Kalia has served as our Chief Information Officer since January 2020. He most recently served as Chief Information and Technology Officer as well as other executive roles at Cylance, Inc., from March 2018 to June 2019, and previously served as Chief Information Officer at Akamai Technologies from October 2011 to February 2018. Prior to Akamai, Mr. Kalia worked at Direct Energy, an energy and services business operating in the U.S. and Canada, from March 2005 to January 2011, and where at the time of his departure he was the Chief Information Officer and Executive Vice President of Customer Operations. Earlier in his career, Mr. Kalia was Vice President and Chief Information Officer of the Business… | Chief Information Officer | SELL | 600 | $78.5K | −23.2% | −21.4%hist |
| 6/10/2026 | Form 4 | GH | Kalia KumudMr. Kalia has served as our Chief Information Officer since January 2020. He most recently served as Chief Information and Technology Officer as well as other executive roles at Cylance, Inc., from March 2018 to June 2019, and previously served as Chief Information Officer at Akamai Technologies from October 2011 to February 2018. Prior to Akamai, Mr. Kalia worked at Direct Energy, an energy and services business operating in the U.S. and Canada, from March 2005 to January 2011, and where at the time of his departure he was the Chief Information Officer and Executive Vice President of Customer Operations. Earlier in his career, Mr. Kalia was Vice President and Chief Information Officer of the Business… | Chief Information Officer | SELL | 5,000 | $652.0K | −23.2% | −21.4%hist |
| 6/5/2026 | Form 4 | GH | Bell Michael BrianMr. Bell has served as our Chief Financial Officer since January 2021. He most recently served as the Chief Financial Officer of CareDx, Inc., a precision medicine company focused on transplantation, from April 2017 to December 2020. From January 2016 to March 2017, Mr. Bell served as the Chief Financial Officer of Metabiota, Inc., a company that develops and sells risk analytics products focused on infectious disease. From May 2012 to January 2016, he served as the Chief Financial Officer of Singulex, Inc., a clinical diagnostics company. Prior to that, Mr. Bell held leadership and executive positions within Novartis, including with Novartis Diagnostics, a global provider of blood screening solutions,… | Chief Financial Officer | SELL | 2,000 | $257.2K | −28.2% | −4.03%hist |
| 6/5/2026 | Form 4 | GH | Eltoukhy Helmy | Co-Chief Executive Officer | SELL | 554 | $72.1K | −28.2% | +8.75%hist |
| 6/5/2026 | Form 4 | GH | Eltoukhy Helmy | Co-Chief Executive Officer | SELL | 900 | $118.6K | −28.2% | +8.75%hist |
| 6/5/2026 | Form 4 | GH | Eltoukhy Helmy | Co-Chief Executive Officer | SELL | 100 | $13.3K | −28.2% | +8.75%hist |
| 6/5/2026 | Form 4 | GH | Eltoukhy Helmy | Co-Chief Executive Officer | SELL | 13,787 | $1.77M | −28.2% | +8.75%hist |
| 6/5/2026 | Form 4 | GH | Eltoukhy Helmy | Co-Chief Executive Officer | SELL | 49,716 | $6.24M | −28.2% | +8.75%hist |
| 6/5/2026 | Form 4 | GH | Eltoukhy Helmy | Co-Chief Executive Officer | SELL | 1,100 | $139.7K | −28.2% | +8.75%hist |
| 6/5/2026 | Form 4 | GH | Eltoukhy Helmy | Co-Chief Executive Officer | SELL | 33,843 | $4.28M | −28.2% | +8.75%hist |
| 6/4/2026 | Form 4 | GH | Krognes Steve E.Steve Krognes has served as a member of our Board since June 2022. Mr. Krognes is a professional independent board member in the biotech and life sciences sector. Before joining the Board, Mr. Krognes was the Chief Financial Officer at Denali Therapeutics Inc., a public biotechnology company, from October 2015 to April 2022. Mr. Krognes joined Denali from Genentech, Inc., a biotechnology company, where he served as Chief Financial Officer and a member of the Executive Committee from April 2009 to September 2015. Mr. Krognes also oversaw Genentech’s Site Services organization between 2011 and 2015, and Genentech’s IT organization between 2009 and 2011. He chaired the Genentech Access to Care Foundation… | Director | SELL | 9,294 | $1.23M | −22.5% | +10.6%hist |
| 6/3/2026 | Form 4 | GH 10b5-1 | Joyce Meghan V.Meghan Joyce has served as a member of our Board since August 2021. She is co-founder and CEO of Duckbill Technologies, Inc., a consumer tech startup, a role she has held since April 2022, and also serves as an independent director and advisor to select high growth organizations in the healthcare and consumer space. Previously, from September 2019 to April 2022, Ms. Joyce served as Chief Operating Officer and Executive Vice President of Platform at Oscar Health, a high-growth health tech and health insurance company, where she led operations, technology, clinical, marketing, and new business lines. Prior to joining Oscar Health, from 2013 to 2019, Ms. Joyce held several leadership roles at Uber… | Director | SELL | 3,516 | $444.8K | −29.4% | −16.4%hist |
| 6/3/2026 | Form 4 | GH 10b5-1 | Joyce Meghan V.Meghan Joyce has served as a member of our Board since August 2021. She is co-founder and CEO of Duckbill Technologies, Inc., a consumer tech startup, a role she has held since April 2022, and also serves as an independent director and advisor to select high growth organizations in the healthcare and consumer space. Previously, from September 2019 to April 2022, Ms. Joyce served as Chief Operating Officer and Executive Vice President of Platform at Oscar Health, a high-growth health tech and health insurance company, where she led operations, technology, clinical, marketing, and new business lines. Prior to joining Oscar Health, from 2013 to 2019, Ms. Joyce held several leadership roles at Uber… | Director | SELL | 650 | $83.2K | −29.4% | −16.4%hist |
| 6/3/2026 | Form 4 | GH 10b5-1 | Joyce Meghan V.Meghan Joyce has served as a member of our Board since August 2021. She is co-founder and CEO of Duckbill Technologies, Inc., a consumer tech startup, a role she has held since April 2022, and also serves as an independent director and advisor to select high growth organizations in the healthcare and consumer space. Previously, from September 2019 to April 2022, Ms. Joyce served as Chief Operating Officer and Executive Vice President of Platform at Oscar Health, a high-growth health tech and health insurance company, where she led operations, technology, clinical, marketing, and new business lines. Prior to joining Oscar Health, from 2013 to 2019, Ms. Joyce held several leadership roles at Uber… | Director | SELL | 106 | $13.7K | −29.4% | −16.4%hist |
| 6/3/2026 | Form 4 | GH 10b5-1 | Joyce Meghan V.Meghan Joyce has served as a member of our Board since August 2021. She is co-founder and CEO of Duckbill Technologies, Inc., a consumer tech startup, a role she has held since April 2022, and also serves as an independent director and advisor to select high growth organizations in the healthcare and consumer space. Previously, from September 2019 to April 2022, Ms. Joyce served as Chief Operating Officer and Executive Vice President of Platform at Oscar Health, a high-growth health tech and health insurance company, where she led operations, technology, clinical, marketing, and new business lines. Prior to joining Oscar Health, from 2013 to 2019, Ms. Joyce held several leadership roles at Uber… | Director | SELL | 5,728 | $728.1K | −29.4% | −16.4%hist |
| 5/28/2026 | Form 4 | GH | Hidalgo Medina Manuel | Director | SELL | 1,000 | $130.1K | −28.3% | −35.5%hist |
| 5/27/2026 | Form 4 | GH 10b5-1 | Saia John G.Mr. Saia has served as our Chief Legal Officer and Corporate Secretary since April 2022, and prior to that as our Senior Vice President, General Counsel and Corporate Secretary from May 2020 to April 2022. Prior to joining Guardant Health, he served as Senior Vice President, General Counsel and Corporate Secretary of WageWorks, Inc., an administrator of consumer-directed benefits, from January 2019 until its acquisition by HealthEquity, Inc. in August 2019, and as General Counsel and Corporate Secretary for AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, from April 2018 to January 2019. Mr. Saia led legal and compliance activities worldwide for both WageWorks and AcelRx. Prior to that, he… | Chief Legal Officer | SELL | 9,994 | $1.25M | −29.3% | +4.62%hist |
| 5/27/2026 | Form 4 | GH 10b5-1 | Saia John G.Mr. Saia has served as our Chief Legal Officer and Corporate Secretary since April 2022, and prior to that as our Senior Vice President, General Counsel and Corporate Secretary from May 2020 to April 2022. Prior to joining Guardant Health, he served as Senior Vice President, General Counsel and Corporate Secretary of WageWorks, Inc., an administrator of consumer-directed benefits, from January 2019 until its acquisition by HealthEquity, Inc. in August 2019, and as General Counsel and Corporate Secretary for AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, from April 2018 to January 2019. Mr. Saia led legal and compliance activities worldwide for both WageWorks and AcelRx. Prior to that, he… | Chief Legal Officer | SELL | 6 | $756.48 | −29.3% | +4.62%hist |
| 5/22/2026 | Form 4 | GH | Freeman Chris | Chief Commercial Officer | SELL | 24,406 | $2.90M | −41.1% | −24.5%hist |
| 5/20/2026 | Form 4 | GH | CLARK IAN TIan Clark has served as a member of our Board since January 2017 and is our lead independent director. Mr. Clark most recently served as CEO, led the Executive Committee, and was a member of the Board of Directors of Genentech Inc., a biotechnology company, from January 2010 to December 2016. In total he served for 14 years at Genentech of which 12 were on the Genentech Executive Committee, initially as Executive Vice President of Commercial Operations. Before that, he served as Senior Vice President and General Manager of BioOncology. Prior to this, Mr. Clark spent 20 years in positions of increasing responsibility at Novartis, Sanofi, Ivax, and Searle, working in the United Kingdom, Canada, Eastern Europe… | Director | SELL | 6,876 | $735.0K | −39.3% | −10.8%hist |
| 5/20/2026 | Form 4 | GH 10b5-1 | Talasaz AmirAli | Co-Chief Executive Officer | SELL | 200 | $20.2K | −39.3% | −3.15%hist |
| 5/20/2026 | Form 4 | GH 10b5-1 | Talasaz AmirAli | Co-Chief Executive Officer | SELL | 37,163 | $4.13M | −39.3% | −3.15%hist |
| 5/20/2026 | Form 4 | GH 10b5-1 | Talasaz AmirAli | Co-Chief Executive Officer | SELL | 900 | $92.3K | −39.3% | −3.15%hist |
| 5/20/2026 | Form 4 | GH 10b5-1 | Talasaz AmirAli | Co-Chief Executive Officer | SELL | 9,852 | $1.07M | −39.3% | −3.15%hist |
| 5/20/2026 | Form 4 | GH 10b5-1 | Talasaz AmirAli | Co-Chief Executive Officer | SELL | 26,352 | $2.97M | −39.3% | −3.15%hist |
| 5/20/2026 | Form 4 | GH 10b5-1 | Talasaz AmirAli | Co-Chief Executive Officer | SELL | 37,900 | $4.25M | −39.3% | −3.15%hist |
| 5/20/2026 | Form 4 | GH 10b5-1 | Talasaz AmirAli | Co-Chief Executive Officer | SELL | 28,908 | $3.18M | −39.3% | −3.15%hist |
| 5/20/2026 | Form 4 | GH 10b5-1 | Talasaz AmirAli | Co-Chief Executive Officer | SELL | 1,366 | $141.8K | −39.3% | −3.15%hist |
| 5/20/2026 | Form 4 | GH 10b5-1 | Talasaz AmirAli | Co-Chief Executive Officer | SELL | 11,919 | $1.25M | −39.3% | −3.15%hist |
| 5/20/2026 | Form 4 | GH 10b5-1 | Talasaz AmirAli | Co-Chief Executive Officer | SELL | 1,200 | $127.1K | −39.3% | −3.15%hist |
| 5/20/2026 | Form 4 | GH 10b5-1 | Talasaz AmirAli | Co-Chief Executive Officer | SELL | 21,171 | $2.27M | −39.3% | −3.15%hist |
| 5/20/2026 | Form 4 | GH 10b5-1 | Talasaz AmirAli | Co-Chief Executive Officer | SELL | 33,069 | $3.58M | −39.3% | −3.15%hist |
| 5/20/2026 | Form 4 | GH 10b5-1 | Saia John G.Mr. Saia has served as our Chief Legal Officer and Corporate Secretary since April 2022, and prior to that as our Senior Vice President, General Counsel and Corporate Secretary from May 2020 to April 2022. Prior to joining Guardant Health, he served as Senior Vice President, General Counsel and Corporate Secretary of WageWorks, Inc., an administrator of consumer-directed benefits, from January 2019 until its acquisition by HealthEquity, Inc. in August 2019, and as General Counsel and Corporate Secretary for AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, from April 2018 to January 2019. Mr. Saia led legal and compliance activities worldwide for both WageWorks and AcelRx. Prior to that, he… | Chief Legal Officer | SELL | 7,181 | $770.0K | −39.3% | +4.62%hist |
| 5/20/2026 | Form 4 | GH 10b5-1 | Saia John G.Mr. Saia has served as our Chief Legal Officer and Corporate Secretary since April 2022, and prior to that as our Senior Vice President, General Counsel and Corporate Secretary from May 2020 to April 2022. Prior to joining Guardant Health, he served as Senior Vice President, General Counsel and Corporate Secretary of WageWorks, Inc., an administrator of consumer-directed benefits, from January 2019 until its acquisition by HealthEquity, Inc. in August 2019, and as General Counsel and Corporate Secretary for AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, from April 2018 to January 2019. Mr. Saia led legal and compliance activities worldwide for both WageWorks and AcelRx. Prior to that, he… | Chief Legal Officer | SELL | 5,632 | $593.3K | −39.3% | +4.62%hist |
| 5/20/2026 | Form 4 | GH 10b5-1 | Saia John G.Mr. Saia has served as our Chief Legal Officer and Corporate Secretary since April 2022, and prior to that as our Senior Vice President, General Counsel and Corporate Secretary from May 2020 to April 2022. Prior to joining Guardant Health, he served as Senior Vice President, General Counsel and Corporate Secretary of WageWorks, Inc., an administrator of consumer-directed benefits, from January 2019 until its acquisition by HealthEquity, Inc. in August 2019, and as General Counsel and Corporate Secretary for AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, from April 2018 to January 2019. Mr. Saia led legal and compliance activities worldwide for both WageWorks and AcelRx. Prior to that, he… | Chief Legal Officer | SELL | 7,187 | $766.9K | −39.3% | +4.62%hist |
| 5/20/2026 | Form 4 | GH | Hidalgo Medina Manuel | Director | SELL | 250 | $26.8K | −39.3% | −35.5%hist |
| 5/20/2026 | Form 4 | GH | Hidalgo Medina Manuel | Director | SELL | 1,000 | $107.1K | −39.3% | −35.5%hist |
| 5/18/2026 | Form 4 | GH 10b5-1 | Tariq MusaMusa Tariq has served as a member of our Board since March 2023. Mr. Tariq is the Founder of Science x Story, a brand driven growth consultancy that creates value at the intersection of business, marketing and organizational strategy. Prior to this, Mr. Tariq served as Chief Marketing Officer of GoFundMe, a crowdfunding platform, from January 2021 to June 2023. He joined GoFundMe to further build the GoFundMe brand and drive the company’s marketing and communications functions. Prior to GoFundMe, Mr. Tariq was Global Head of Marketing for Airbnb Experiences, a division of Airbnb, Inc., a provider of an online marketplace for short-term homestays and experiences, from September 2018 to December 2020 where he… | Director | SELL | 116 | $11.1K | −69.0% | −57.4%hist |
| 5/12/2026 | Form 4 | GH 10b5-1 | Talasaz AmirAli | Co-Chief Executive Officer | SELL | 50,000 | $5.02M | −67.3% | −3.15%hist |
| 4/16/2026 | Form 4 | GH 10b5-1 | Tariq MusaMusa Tariq has served as a member of our Board since March 2023. Mr. Tariq is the Founder of Science x Story, a brand driven growth consultancy that creates value at the intersection of business, marketing and organizational strategy. Prior to this, Mr. Tariq served as Chief Marketing Officer of GoFundMe, a crowdfunding platform, from January 2021 to June 2023. He joined GoFundMe to further build the GoFundMe brand and drive the company’s marketing and communications functions. Prior to GoFundMe, Mr. Tariq was Global Head of Marketing for Airbnb Experiences, a division of Airbnb, Inc., a provider of an online marketplace for short-term homestays and experiences, from September 2018 to December 2020 where he… | Director | SELL | 116 | $9.8K | −90.2% | −57.4%hist |
| 4/6/2026 | Form 4 | GH 10b5-1 | Monroe Terilyn J.Ms. Monroe has served as our Chief People Officer since January 2024. She most recently served as Chief People Officer at Bonterra, a SaaS, PE backed company focused on accelerating social impact through technology, from November 2021 to September 2023, and previously served as Chief People Officer, SVP People & Places at Varian from October 2017 to April 2021. Prior to Varian, Ms. Monroe worked as Chief People & Culture Officer, SVP Human Resources at Acxiom from 2015 to 2017. She also was Chief Diversity Officer at Intuit, where she led the company’s diversity and inclusion efforts, and held various roles in the Human Resources organization from 2002 to 2015. Ms. Monroe serves on the board of directors… | Chief People Officer | SELL | 3,832 | $355.1K | −88.3% | −31.0%hist |
| 3/18/2026 | Form 4 | GH 10b5-1 | Tariq MusaMusa Tariq has served as a member of our Board since March 2023. Mr. Tariq is the Founder of Science x Story, a brand driven growth consultancy that creates value at the intersection of business, marketing and organizational strategy. Prior to this, Mr. Tariq served as Chief Marketing Officer of GoFundMe, a crowdfunding platform, from January 2021 to June 2023. He joined GoFundMe to further build the GoFundMe brand and drive the company’s marketing and communications functions. Prior to GoFundMe, Mr. Tariq was Global Head of Marketing for Airbnb Experiences, a division of Airbnb, Inc., a provider of an online marketplace for short-term homestays and experiences, from September 2018 to December 2020 where he… | Director | SELL | 348 | $30.7K | −45.9% | −92.3% |
Chart shows split-adjusted close for the last three years, or the selected date range. Triangles mark open-market Form 4 purchases and sales in that window.